India's Cipla gets tentative U.S. nod for HIV tablets
MUMBAI (Reuters) - Indian drugmaker Cipla has received a tentative U.S. FDA approval for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs, the drug regulator's website showed.
Cipla sells the combination drug under the brand name 'Duovir N' outside the United States.
The company plans to use a different brand name in the U.S. for this drug, S. Radhakrishnan, a director on Cipla board told Reuters.
(Reporting by Kaustubh Kulkarni; Editing by Anupama Dwivedi)
- Tweet this
- Share this
- Digg this
- Children's corpses reveal desperate attempts to escape Korean ferry |
- Russia says it will respond if Ukraine interests attacked |
- Australia, Malaysia vow to keep searching to solve plane mystery
- Search for MH370 reveals a military vulnerability for China
- UK says scrambles jets to see off Russian planes near Scotland